GlaxoSmithKline reports positive clinical data for new COPD therapy

GlaxoSmithKline has announced the findings of a new clinical study that affirm the benefits offered by its chronic obstructive pulmonary disease (COPD) therapy Anoro Ellipta.

The company and its development partner Inoviva have reported clinical trial data showing how Anoro Ellipta, a combination therapy bringing together umeclidinium and vilanterol (UMEC/VI), can offer a better performance than a tiotropium/olodaterol (TIO/OLO) regimen.

In the eight-week study of 236 patients with COPD, UMEC/VI demonstrated superiority to TIO/OLO in terms of lung function improvements, with both treatments offering a comparable tolerability and safety profile.

This represents a first-in-class head-to-head comparison of two fixed-dose once-daily therapies combining a long-acting muscarinic antagonist with a long-acting beta agonist, a class of treatments that has thus far seen a lack of differentiation.

Eric Dube, senior vice-president and head of GlaxoSmithKline's global respiratory business, said: "The data demonstrates that UMEC/VI provides superior lung function improvements to the comparator TIO/OLO."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.